Skip to content

Pumitamig

DRUG17 trials

Sponsors

Bristol-Myers Squibb, BioNTech SE, M.D. Anderson Cancer Center

Conditions

Advanced Renal Cell Carcinoma (RCC)Advanced Solid TumorBreast CancerBreast NeoplasmsExtensive-stage Small-cell Lung CancerHepatocellular Carcinoma (HCC)Lung CancerNon-Small Cell Lung Cancer

Phase 1

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RecruitingNCT06618287
Bristol-Myers SquibbBreast Cancer, Lung Cancer
Start: 2025-02-04End: 2031-02-26Target: 416Updated: 2026-05-07
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
RecruitingNCT07070232
BioNTech SEAdvanced Solid Tumor
Start: 2025-08-12End: 2029-10-01Target: 980Updated: 2026-05-22
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
RecruitingNCT07147348
BioNTech SEAdvanced Solid Tumor
Start: 2025-08-27End: 2028-08-01Target: 375Updated: 2026-04-06
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
RecruitingNCT07291076
Bristol-Myers SquibbHepatocellular Carcinoma (HCC)
Start: 2026-03-16End: 2031-10-14Target: 129Updated: 2026-05-14
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
RecruitingNCT07293351
Bristol-Myers SquibbAdvanced Renal Cell Carcinoma (RCC)
Start: 2026-03-26End: 2031-11-26Target: 234Updated: 2026-05-13
Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer
Not yet recruitingNCT07579221
M.D. Anderson Cancer CenterNon-Small Cell Lung Cancer
Start: 2026-11-30End: 2031-08-01Target: 17Updated: 2026-05-12

Phase 2

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
RecruitingNCT06712316
BioNTech SENon-small Cell Lung Cancer
Start: 2025-01-07End: 2030-03-01Target: 1260Updated: 2026-05-22
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
RecruitingNCT06841055
BioNTech SENon-small Cell Lung Cancer
Start: 2025-03-03End: 2028-10-01Target: 60Updated: 2026-04-24
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
RecruitingNCT07221357
Bristol-Myers SquibbUntreated, Unresectable, or Metastatic Colorectal Cancer
Start: 2025-12-31End: 2034-03-11Target: 990Updated: 2026-05-06
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
RecruitingNCT07221149
Bristol-Myers SquibbUntreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Start: 2026-03-13End: 2032-09-11Target: 690Updated: 2026-05-14
A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
RecruitingNCT07255404
BioNTech SEPancreatic Ductal Adenocarcinoma (PDAC)
Start: 2025-12-04End: 2028-08-01Target: 105Updated: 2026-04-29
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
RecruitingNCT07297212
BioNTech SERecurrent Glioblastoma
Start: 2026-01-15End: 2029-07-01Target: 75Updated: 2026-04-29
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Not yet recruitingNCT07492680
Bristol-Myers SquibbSolid Tumors
Start: 2026-07-17End: 2032-05-20Target: 260Updated: 2026-03-25

Phase 3

Related Papers